Pharma Journalist -

Shandong Fontacea Pharmaceutical Co. Ltd. announced that it has entered into an exclusive license, development and commercialization agreement with Janssen Biotech, Inc., to develop and…
Read More...

BioArctic AB (publ) announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The…
Read More...

Triplet Therapeutics, Inc., a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, launched today with $59 million in…
Read More...

CytoDyn Inc. and Vyera Pharmaceuticals, LLC announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize…
Read More...

Roche and Spark Therapeutics, Inc. announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger…
Read More...

AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs…
Read More...

Organovo Holdings, Inc. and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines,…
Read More...

UMass Medical School and GE Healthcare Life Sciences will establish a new large-scale viral vector manufacturing facility, able to provide large quantities of high-quality recombinant…
Read More...

Charles River Laboratories International, Inc. and HemaCare Corporation announced a definitive agreement for Charles River to acquire HemaCare for approximately $380 million in cash.…
Read More...

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) for the…
Read More...